tbuckley/cabot-search huggingface dataset:
PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy
Authors: Feng Yue, Changyou Song, Di Huang, Naagarajan Narayanan, Jiamin Qiu, Zhihao Jia, Zhengrong Yuan, Stephanie N. Oprescu, Bruno T. Roseguini, Meng Deng, Shihuan Kuang
Journal: Molecular Therapy (2020)

Duchenne muscular dystrophy (DMD) is caused by a mutation of the muscle membrane protein dystrophin and characterized by severe degeneration of myofibers, progressive muscle wasting, loss of mobility, and, ultimately, cardiorespiratory failure and premature death. Currently there is no cure for DMD. Herein, we report that skeletal muscle-specific knockout (KO) of the phosphatase and tensin homolog (Pten) gene in an animal model of DMD (mdx mice) alleviates myofiber degeneration and restores muscle function without increasing tumor incidence. Specifically, Pten KO normalizes myofiber size and prevents muscular atrophy, and it improves grip strength and exercise performance in mdx mice. Pten KO also reduces fibrosis and inflammation, and it ameliorates muscle pathology in mdx mice. Unbiased RNA sequencing reveals that Pten KO upregulates extracellular matrix and basement membrane components positively correlated with wound healing and suppresses negative regulators of wound healing and lipid biosynthesis, thus improving the integrity of muscle basement membrane at the ultrastructural level. Importantly, pharmacological inhibition of PTEN similarly ameliorates muscle pathology and improves muscle integrity and function in mdx mice. Our findings provide evidence that PTEN inhibition may represent a potential therapeutic strategy to restore muscle function in DMD. Duchenne muscular dystrophy (DMD) is caused by a mutation of the muscle membrane protein dystrophin and characterized by severe degeneration of myofibers, progressive muscle wasting, loss of mobility, and, ultimately, cardiorespiratory failure and premature death. Currently there is no cure for DMD. Herein, we report that skeletal muscle-specific knockout (KO) of the phosphatase and tensin homolog (Pten) gene in an animal model of DMD (mdx mice) alleviates myofiber degeneration and restores muscle function without increasing tumor incidence. Specifically, Pten KO normalizes myofiber size and prevents muscular atrophy, and it improves grip strength and exercise performance in mdx mice. Pten KO also reduces fibrosis and inflammation, and it ameliorates muscle pathology in mdx mice. Unbiased RNA sequencing reveals that Pten KO upregulates extracellular matrix and basement membrane components positively correlated with wound healing and suppresses negative regulators of wound healing and lipid biosynthesis, thus improving the integrity of muscle basement membrane at the ultrastructural level. Importantly, pharmacological inhibition of PTEN similarly ameliorates muscle pathology and improves muscle integrity and function in mdx mice. Our findings provide evidence that PTEN inhibition may represent a potential therapeutic strategy to restore muscle function in DMD.
1259O A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)
Authors: Y. Toi, H. Hayashi, D. Fujimoto, M. Tachihara, N. Furuya, S. Otani, J. Shimizu, N. Katakami, K. Azuma, N. Miura, K. Nishino, S. Hara, S. Teraoka, S. Morita, K. Nakagawa, N. Yamamoto
Journal: Annals of Oncology (2020)
1215O - SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
Authors: B. Besse, J. Adam, N. Cozic, N. Chaput-Gras, D. Planchard, L. Mezquita, J. Remon Masip, P. Lavaud, C. Naltet, A. Gazzah, V. Thomas de Montpreville, M.-R. Ghigna, S. Mussot, E. Fadel, L. Mabille, B. Duchemann, F. Barlesi, J-C. Soria, C. Caramella, O. Mercier
Journal: Annals of Oncology (2020)

Neoadjuvant immune checkpoint inhibitors induce major pathologic response (MPR) rates in 17- 45% of NSCLCs. We report the results of a phase 2 trial of neoadjuvant A for NSCLC. Patient (pts) with clinical stage IA (≥ 2 cm)-IIIA non N2 NSCLC eligible for surgery, PS 0-1, received 1 injection of A (1200 mg IV D1) followed by surgery between D21-D28. The primary endpoint was the rate of pts without major toxicities or morbidities from D1 until 1 month after the surgery. Fresh tumour tissue was analysed within 4 hours after surgery. Response by RECIST1.1 and major pathological response (MPR; ≤10% viable tumour) were assessed. From December 2016 to February 2020, 30 pts were enrolled in two centres. The mean age of pts was 64, 50% were female, 7% never smokers, 83% had adenocarcinomas. Pathological stages were I (n=15, 50%), II (n=6, 20%) III (n=9, 30%). All pts had their planned surgery, none were delayed by >15 days. 29 had R0 resection, 1 had R1. Three pts experienced surgical complications: 1 respiratory distress grade 3 with sepsis grade 4, 1 heart block atrioventricular and 1 paresthesia grade 1. There was no grade 5 toxicity. Treatment-related adverse effects (TRAEs) included only one grade 1 parietal pain related to surgery. No RECIST radiological response and no MPR were observed. After A, 15/29 tumours were PD-L1 TC3 or IC3 based on the SP142 assay. 17/30 (56%) tumours had necrosis (med. 5% of tumour surface, 0-80). 20/29 cases had histopathological features of response according to the immune-related pathologic response criteria (irPRC), with isolated or combined features of immune activation (19/20), tissue repair (15/20) and/or tumour cell death (9/20).NGS (11 genes) was performed in 23 tumours resulting in 14 TP53 mutations (mut), 7 KRAS mutations , 3 EGFR mutations, 1 wild-type, 1 STK11 mutations (in a tumour with 80% necrosis). Surgery after one infusion of A was safe. The short delay between A and surgery might explain the absence of MPR.
Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study
Authors: Ania Wajnberg, Mayce Mansour, Emily Leven, Nicole M Bouvier, Gopi Patel, Adolfo Firpo-Betancourt, Rao Mendu, Jeffrey Jhang, Suzanne Arinsburg, Melissa Gitman, Jane Houldsworth, Emilia Sordillo, Alberto Paniz-Mondolfi, Ian Baine, Viviana Simon, Judith Aberg, Florian Krammer, David Reich, Carlos Cordon-Cardo
Journal: The Lancet Microbe (2020)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic. The proportion of infected individuals who seroconvert is still an open question. In addition, it has been shown in some individuals that viral genome can be detected up to 3 months after symptom resolution. We investigated both seroconversion and PCR positivity in a large cohort of convalescent serum donors in the New York City (NY, USA) region.In this observational study, we ran an outreach programme in the New York City area. We recruited participants via the REDCap (Vanderbilt University, Nashville, TN, USA) online survey response. Individuals with confirmed or suspected SARS-CoV-2 infection were screened via PCR for presence of viral genome and via ELISA for presence of anti-SARS-CoV-2 spike antibodies. One-way ANOVA and Fisher's exact test were used to measure the association of age, gender, symptom duration, and days from symptom onset and resolution with positive antibody results.Between March 26 and April 10, 2020, we measured SARS-CoV-2 antibody titres in 1343 people. Of the 624 participants with confirmed SARS-CoV-2 infection who had serologies done after 4 weeks, all but three seroconverted to the SARS-CoV-2 spike protein, whereas 269 (37%) of 719 participants with suspected SARS-CoV-2 infection seroconverted. PCR positivity was detected up to 28 days from symptom resolution.Most patients with confirmed COVID-19 seroconvert, potentially providing immunity to reinfection. We also report that in a large proportion of individuals, viral genome can be detected via PCR in the upper respiratory tract for weeks after symptom resolution, but it is unclear whether this signal represents infectious virus. Analysis of our large cohort suggests that most patients with mild COVID-19 seroconvert 4 weeks after illness, and raises questions about the use of PCR to clear positive individuals.None.
154P Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)
Authors: Y. Chao, S. Yang, Y. Zhang, Z. Shen, X. Wu, J. Wang, M. Quiroz, A. Nielsen, C. Liu, J. Desai
Journal: Annals of Oncology (2020)
1331P Correlation between development and grade of immune-related toxicities and outcomes during treatment with immune checkpoint inhibitors in non-small cell lung cancer patients
Authors: P. Ayala de Miguel, J. López Gallego, I. Gorospe García, P.R. Rivera Vargas, A. Posada Restrepo, A. Acero Caballero, J. Aires Machado, R. Alonso Calderón, J.M. Rodríguez García, P. Borrega García
Journal: Annals of Oncology (2020)
641P Real-world patterns of genomic testing in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: N. Shore, R. Ionescu-Ittu, L. Yang, F. Laliberté, S. Payne, A. Gayle, S. Amin, M. Mahendran, D. Lejeune, L. Yu, J. Burgents, M.S. Duh, S. Ghate
Journal: Annals of Oncology (2020)
1160O An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis
Authors: G.P. Nicolas, C. Ansquer, N.P. Lenzo, H. Grønbæk, A. Haug, S. Navalkissoor, J-M. Beauregard, N. Germann, S. McEwan, D. Wild, R.J. Hicks
Journal: Annals of Oncology (2020)
283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial
Authors: N. Turner, R. Dent, J. O'Shaughnessy, S-B. Kim, S. Isakoff, C.H. Barrios, S. Saji, I. Bondarenko, Z. Nowecki, Q. Lian, S-J. Reilly, H. Hinton, M. Wongchenko, A. Mani, M. Oliveira
Journal: Annals of Oncology (2020)
783P Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- (1L) or second-line (2L) PD-1 and PD-L1 inhibitors in the United States (US)
Authors: M. Boyd, S. Annavarapu, G.K. Doshi, K. Imai, E.I. Sbar, J.L. Godwin, H. Li, G. Sonpavde
Journal: Annals of Oncology (2020)
Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Authors: Kevin A. Nguyen, Alan Lee, Sagar A. Patel, Arun Chakravorty, James B. Yu, Amar U. Kishan, Albert J. Chang
Journal: JAMA Network Open (2020)

This cohort study examines trends in the use of brachytherapy, external beam radiotherapy, and stereotactic body radiation therapy for disease management in patients with localized prostate cancer and compares outcomes between these therapies.
A Prognostic Predictive System Based on Deep Learning for Locoregionally Advanced Nasopharyngeal Carcinoma
Authors: Mengyun Qiang, Chaofeng Li, Yuyao Sun, Ying Sun, Liangru Ke, Chuanmiao Xie, Tao Zhang, Yujian Zou, Wenze Qiu, Mingyong Gao, Yingxue Li, Xiang Li, Zejiang Zhan, Kuiyuan Liu, Xi Chen, Chixiong Liang, Qiuyan Chen, Haiqiang Mai, Guotong Xie, Xiang Guo, Xing Lv
Journal: JNCI Journal of the National Cancer Institute (2020)

Abstract Background Images from magnetic resonance imaging (MRI) are crucial unstructured data for prognostic evaluation in nasopharyngeal carcinoma (NPC). We developed and validated a prognostic system based on the MRI features and clinical data of locoregionally advanced NPC (LA-NPC) patients to distinguish low-risk patients with LA-NPC for whom concurrent chemoradiotherapy (CCRT) is sufficient. Methods This multicenter, retrospective study included 3444 patients with LA-NPC from January 1, 2010, to January 31, 2017. A 3-dimensional convolutional neural network was used to learn the image features from pretreatment MRI images. An eXtreme Gradient Boosting model was trained with the MRI features and clinical data to assign an overall score to each patient. Comprehensive evaluations were implemented to assess the performance of the predictive system. We applied the overall score to distinguish high-risk patients from low-risk patients. The clinical benefit of induction chemotherapy (IC) was analyzed in each risk group by survival curves. Results We constructed a prognostic system displaying a concordance index of 0.776 (95% confidence interval [CI] = 0.746 to 0.806) for the internal validation cohort and 0.757 (95% CI = 0.695 to 0.819), 0.719 (95% CI = 0.650 to 0.789), and 0.746 (95% CI = 0.699 to 0.793) for the 3 external validation cohorts, which presented a statistically significant improvement compared with the conventional TNM staging system. In the high-risk group, patients who received induction chemotherapy plus CCRT had better outcomes than patients who received CCRT alone, whereas there was no statistically significant difference in the low-risk group. Conclusions The proposed framework can capture more complex and heterogeneous information to predict the prognosis of patients with LA-NPC and potentially contribute to clinical decision making.
361O Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study
Authors: M. Caccese, M. Simonelli, L. Bellu, V. Villani, S. Rizzato, T. Ius, F. Pasqualetti, M. Russo, F. Franchino, R. Amoroso, R. Bertorelle, F. Cavallin, A. Dipasquale, M. Carosi, S. Pizzolitto, D. Cesselli, M.P. Gardiman, M. Padovan, V. Zagonel, G. Lombardi
Journal: Annals of Oncology (2020)
1490P Evaluation of circulating tumor cells in esophageal carcinoma patients who received chemotherapy or neoadjuvant chemotherapy
Authors: M. Takuro, E. Endo, D. Ujiie, K. Kase, H. Nakano, N. Yamauchi, L. Yamada, A. Kaneta, Y. Kanke, H. Hanayama, Y. Watanabe, S. Nakajima, S. Hayase, H. Okayama, M. Saito, Z. Saze, T. Momma, K. Mimura, K. Kono
Journal: Annals of Oncology (2020)
1944P Hyperglycemia increased nivolumab-induced cardiotoxicity, enhanced immunoresistance of ERɑ+, PR+, HER2- breast cancer cells modulating growth factors and NLRP3 expression
Authors: V. Quagliariello, A. Bonelli, A. Caronna, C. Lombari, I. Grimaldi, G. Conforti, G. Botti, N. Maurea
Journal: Annals of Oncology (2020)
1409P Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SqCLC) targeted therapy
Authors: M.M. Skupinska, T. Obtulowicz, J. Moes-Sosnowska, A. Rozy, E. Szczepulska, R. Langfort, J. Chorostowska Wynimko, A. Stanczak, J. Pieczykolan, M. Wieczorek, D. Popiel
Journal: Annals of Oncology (2020)
164MO Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results
Authors: I. Grote, S. Bartels, L. Kandt, L. Bollmann, H. Christgen, M. Gronewold, O. Gluz, U. Nitz, S. Kümmel, M. Braun, B. Aktas, E-M. Grischke, C. Schumacher, K. Lüdtke-Heckenkamp, R. Kates, R. Wuerstlein, M. Gräser, N. Harbeck, M. Christgen, H. Kreipe
Journal: Annals of Oncology (2020)
689TiP NRG Oncology’s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)
Authors: Z. Zumsteg, T. Karrison, M.D. Michaelson, P. Tran, R. Kudchadker, F. Feng
Journal: Annals of Oncology (2020)
Short-lived and extended half-life target modules for redirecting UniCAR T-cells against sialyl-Tn expressing cancer cells
Authors: Liliana Raquel Rodrigues Loureiro, Anja Feldmann, Ralf Bergmann, Stefanie Koristka, Nicole Berndt, Nikolett Hegedus, Domokos Mathe, Paula Videira, Michael Bachmann, Claudia Arndt
Journal: Journal for ImmunoTherapy of Cancer (2019)
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
Authors: M. Lambertini, F.A. Peccatori, I. Demeestere, F. Amant, C. Wyns, J.-B. Stukenborg, S. Paluch-Shimon, M.J. Halaska, C. Uzan, J. Meissner, M. von Wolff, R.A. Anderson, K. Jordan
Journal: Annals of Oncology (2020)
Unraveling the Obesity Paradox Through Bariatric Surgery
Authors: Dharmenaan Palamuthusingam, Reza Reyaldeen, Dev Jegatheesan
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
39P Analysis of bloodstream infections in oncological patients
Authors: M. Blanco Clemente, C. Traseira Puchol, B. Núñez García, J.C. Sánchez González, M. Mendez Garcia, L. Gutiérrez Sanz, M. Provencio Pulla, A. Ramos Martínez, E. Muñez Rubio, A. Callejas Díaz, A. Fernández-Cruz
Journal: Annals of Oncology (2020)
LBA22 Imaging based PCa screening among BRCA mutation carriers: Results from the first round of screening
Authors: D. Margel, Y. Ber, N. Segal, O. Benjaminov, S. Tamir, M. Yakimov, I. Kedar, S. Sela, R. Ozalvo, L. Shavit-Grievink, D. Kedar, J. Baniel, E. Rosenbaum
Journal: Annals of Oncology (2020)
1290P Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC)
Authors: O. Gautschi, A. Drilon, D.S.W. Tan, G.R. Oxnard, C. McCoach, K. Goto, K. Park, G. Alonso Casal, F. de Braud, P. French, V. Soldatenkova, B. Besse
Journal: Annals of Oncology (2020)
1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)
Authors: L. Paz-Ares, T.M. Kim, D. Vicente, E. Felip, D.H. Lee, K.H. Lee, C-C. Lin, M.J. Flor, M. Di Nicola, R.M. Alvarez, C. Helwig, L.S. Ojalvo, J. Gulley, B.C. Cho
Journal: Annals of Oncology (2020)
916MO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC)
Authors: C. Aggarwal, N.F. Saba, A.P. Algazi, A. Sukari, T. Seiwert, M. Haigentz, M. Porosnicu, M. Bonomi, J. Boyer, N. Durham, R. Kumar, K. Laubscher, M. Gong, N. Ceaicovscaia, A. Gascó Hernández
Journal: Annals of Oncology (2020)
851P PLA2G7/PAF-AH as protective factor and potential negative regulator of the Wnt signaling pathway in BRCA1 mutant ovarian cancer
Authors: Y. Liao, S. Badmann, T. Kaltofen, D. Mayr, E. Schmoeckel, E. Deuster, M. Mannewitz, S. Landgrebe, T. Kolben, A. Hester, S. Beyer, A. Burges, S. Mahner, U. Jeschke, F. Trillsch, B. Czogalla
Journal: Annals of Oncology (2020)
Unravelling the Obesity Paradox Through Bariatric Surgery—Reply
Authors: Kyle H. Sheetz, Seth A. Waits
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction
Authors: Vatche G. Agopian, Daniela Markovic, Goran B. Klintmalm, Giovanna Saracino, William C. Chapman, Neeta Vachharajani, Sander S. Florman, Parissa Tabrizian, Brandy Haydel, David Nasralla, Peter J. Friend, Yuri L. Boteon, Rutger Ploeg, Michael P. Harlander-Locke, Victor Xia, Joseph DiNorcia, Fady M. Kaldas, Hasan Yersiz, Douglas G. Farmer, Ronald W. Busuttil
Journal: Journal of Hepatology (2020)